Teduglutide is a glucagon-like peptide-2 (GLP-2) analog used to treat patients with Short Bowel Syndrome (SBS) who require parenteral nutritional support. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology.
- Mechanism
- Curator reviewed
Teduglutide is an analog of naturally occurring human glucagon-like peptide-2 (GLP-2), a peptide secreted by L-cells of the distal intestine in response to meals. GLP-2 increases intestinal and portal blood flow and inhibit gastric acid secretion. Teduglutide binds to the glucagon-like peptide-2 receptors located in enteroendocrine cells, subepithelial myofibroblasts and enteric neurons of the submucosal and myenteric plexus. This causes the release of insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF). These growth factors may contribute to the increase in crypt cell growth and surface area of the gastric mucosa. Ultimately, absorption through the intestine is enhanced.
- Primary indication
- Teduglutide is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.Curator reviewed · 1 structured indication
- Formula / weight
- C164H252N44O55S · 3752.0 Da
- First approval
- Canada, 2020 · United States, 2012 · European Union, 2016
- Also known as
- (Gly2)GLP-2 · Glucagon-like peptide II (2-glycine) (human) · Gly(2)-GLP-2 · Teduglutide [rDNA origin] · Teduglutide Recombinant
- Code names
- ALX-0600
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Teduglutide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account